Two Sigma Investments LP Purchases 181,146 Shares of Encompass Health Co. (NYSE:EHC)

Two Sigma Investments LP boosted its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 149.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 302,317 shares of the company's stock after buying an additional 181,146 shares during the quarter. Two Sigma Investments LP owned approximately 0.30% of Encompass Health worth $27,919,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EHC. T. Rowe Price Investment Management Inc. acquired a new position in Encompass Health during the 4th quarter worth about $152,953,000. Norges Bank acquired a new position in shares of Encompass Health in the 4th quarter valued at about $100,637,000. Raymond James Financial Inc. acquired a new position in shares of Encompass Health in the 4th quarter valued at about $77,944,000. Jennison Associates LLC acquired a new position in shares of Encompass Health in the 4th quarter valued at about $52,094,000. Finally, Farallon Capital Management LLC lifted its stake in shares of Encompass Health by 15,266.7% in the 4th quarter. Farallon Capital Management LLC now owns 461,000 shares of the company's stock valued at $42,573,000 after purchasing an additional 458,000 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. KeyCorp boosted their price objective on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a research note on Tuesday. UBS Group boosted their target price on Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research report on Monday, April 28th. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Royal Bank of Canada boosted their target price on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Finally, Barclays boosted their target price on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $122.71.

Encompass Health Stock Up 1.6%

Shares of Encompass Health stock traded up $1.88 on Tuesday, hitting $120.78. The company had a trading volume of 71,595 shares, compared to its average volume of 787,034. The stock has a market capitalization of $12.17 billion, a price-to-earnings ratio of 27.08, a P/E/G ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a 1 year low of $82.74 and a 1 year high of $121.96. The stock has a 50 day moving average of $108.24 and a 200-day moving average of $101.51. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.19 by $0.18. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.12 earnings per share. As a group, sell-side analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's dividend payout ratio is presently 14.05%.

Insider Activity

In other news, CEO Mark J. Tarr sold 118,384 shares of the company's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the completion of the transaction, the chief executive officer now directly owns 527,070 shares of the company's stock, valued at $64,054,817.10. This represents a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now directly owns 11,958 shares of the company's stock, valued at approximately $1,394,422.38. This represents a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock valued at $16,034,082 over the last three months. Corporate insiders own 2.00% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.